The pulmonary artery catheter market has seen considerable growth due to a variety of factors.
• In recent times, the market size of the pulmonary artery catheter has been increasing steadily. From $1.2 billion in 2024, it's predicted to escalate to $1.26 billion by 2025, marking a compound annual growth rate (CAGR) of 4.9%.
Factors contributing to this upward trend during the historical period include an aging population, a surge in minimally invasive surgeries, a high ratio of diabetes and hypertension cases, a growing number of cardiovascular and pulmonary diseases, and an augmented demand for sophisticated hemodynamic monitoring systems.
The pulmonary artery catheter market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the pulmonary artery catheter market to consistently expand in the coming years, reaching an estimated worth of $1.51 billion in 2029 with a compound annual growth rate (CAGR) of 4.6%.
A surge in health issues related to inactive and unhealthy lifestyle choices, heightened smoking and alcohol consumption, boosted investment in healthcare, escalating instances of cardiac and pulmonary diseases, and increased spending on health care have all been credited for this upward trend. The projection period also sees a rising trend towards non-invasive or slightly invasive methods like echocardiography, as well as less invasive hemodynamic monitoring devices. Sterilization methods, accurate catheter placement validation, continuous complication monitoring, combination with sophisticated monitoring systems, and personalization of hemodynamic monitoring are paving the way for future advancements.
The pulmonary artery catheter market is predicted to expand due to the escalating prevalence of cardiac and pulmonary ailments. Multiple factors can be associated with the surge, including poor dietary habits, inactive lifestyle, environmental and societal influences, as well as lack of diagnosis and treatment. A pulmonary artery catheter is a device designed to monitor the pressure in the pulmonary artery, enabling diagnosis and management of cardiac and pulmonary diseases. As reported by the Australian Institute of Health and Welfare in June 2024, it was estimated that about 638,000 individuals, or 2.5% of the population, suffered from chronic obstructive pulmonary disease in Australia in 2022. Moreover, the Centers for Disease Control and Prevention stated in May 2024 that heart disease was responsible for approximately 702,880 deaths in 2022 in the United States, accounting for one fifth of the total mortality rate. As a result, the mounting prevalence of cardiac and pulmonary diseases is a key driver for the growth of the pulmonary artery catheter market.
The pulmonary artery catheter market covered in this report is segmented –
1) By Product: Four Lumen Artery Catheter, Five Lumen Artery Catheter, Six Lumen Artery Catheter, Other Product Types
2) By Application: Intensive Care Units (ICUs), Non-Intensive Care Units (ICUs), Other Applications
3) By Model Of Delivery: Hospitals, Long Term Care Facilities, Other End Users
Subsegments:
1) By Four Lumen Artery Catheter: Standard Four Lumen Catheter, Thermodilution Four Lumen Catheter, Specialty Four Lumen Catheter
2) By Five Lumen Artery Catheter: Standard Five Lumen Catheter, Thermodilution Five Lumen Catheter, Specialty Five Lumen Catheter
3) By Six Lumen Artery Catheter: Standard Six Lumen Catheter, Thermodilution Six Lumen Catheter, Specialty Six Lumen Catheter
4) By Other Product Types: Introducer Sheath Catheters, Pressure Monitoring Catheters, Specialty Catheters, Disposable Pulmonary Artery Catheters
Leading corporations in the pulmonary artery catheter market are dedicating their efforts towards the creation of innovative devices like endovascular catheters. These products are designed to improve the precision of hemodynamic monitoring, boost patient safety, and simplify minimally invasive assessments of cardiac health and pulmonary pressures. The endovascular catheter, a special tool, permits exact catheterization and the monitoring of the pulmonary artery. For instance, in January 2024, Thrombolex Inc., an American medical device company, introduced the BASHIR .035 and BASHIR S-B endovascular catheters, specifically designed to treat acute pulmonary embolism (PE). These catheters, engineered to operate with a 0.035 guidewire, have a unique expandable infusion basket mechanism that enables targeted thrombolysis by directly inserting thrombolytics into the clot. This method aims to expedite the restoration of blood flow, enhancing patient safety and decreasing the time required for the procedure.
Major companies operating in the pulmonary artery catheter market are:
• Cardinal Health Corp
• Medtronic Inc.
• Becton Dickinson And Company
• Philips Healthcare Corp
• Stryker Corporation
• Boston Scientific Corporation
• Medline Industries Inc.
• B. Braun Melsungen AG
• Terumo Corporation
• Edwards Lifesciences Corporation
• Zoll Medical Corporation
• Nipro Corporation
• Smiths Medical Group
• Teleflex Incorporated
• Merit Medical Systems Inc.
• DeRoyal Industries Inc.
• Vygon SA
• AngioDynamics Inc.
• Relisys Medical Devices Limited
• QXMédical LLC
North America was the largest region in the pulmonary artery catheter market in 2024. The regions covered in the pulmonary artery catheter market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.